# Intensity Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intensity-therapeutics

- Industry: Biotechnology
- Headquarters: Norwalk, US
- Website: www.intensitytherapeutics.com
- Total disclosed funding: $10M
- Latest round: Series A (Jun 28, 2016)
- Investors on record: 3

## About

Based in the US, Intensity Therapeutics, Inc. is a biotechnology firm focusing on advanced cancer treatment solutions through innovative intratumoral delivery technology.Founded in 2012 and headquartered in Norwalk, US, Intensity Therapeutics, Inc. specializes in developing therapies for solid tumors. The company has completed 4 deals, with its most recent deal occurring on July 3, 2023, during which it raised USD 19.5 million in an IPO. Lewis Bender serves as both the CEO and co-founder, contributing his experience to drive the company's vision.Intensity Therapeutics specializes in innovative cancer treatment solutions through its proprietary intratumoral delivery technology. The company's core offering, INT230-6, leverages its DfuseRx? penetration enhancer platform to enable therapeutic agents to be injected directly into solid tumors, resulting in improved absorption and enhanced diffusion of drugs into cancer cells. This localized treatment approach aims to facilitate cancer cell death while simultaneously activating a systemic immune response, thereby allowing immune cells to effectively target and attack tumors throughout the body. The primary end users include patients with metastatic cancer, especially those undergoing presurgical interventions, as well as healthcare providers in oncology and clinical research settings. Intensity Therapeutics markets its products primarily in North America and Europe, seeking to address critical needs within these regions' cancer treatment frameworks.The revenue model for Intensity Therapeutics revolves around the sale of its flagship product, INT230-6, and potentially future products developed through its proprietary technology platform. Transactions are structured through partnerships with healthcare institutions, clinical trial collaborations, and possibly direct sales to oncology practices, where the drug would be administered to patients. The company may also engage in collaborations with pharmaceutical companies or research organizations for further development and commercialization of its drug candidates. Given the nature of these products, pricing strategies could be aligned with value-based pricing models that reflect the therapeutic benefits provided to patients. The company reported an EBITDA of USD -16.59 mn for the most recent year, 2024.In July 2023, Intensity Therapeutics, Inc. raised USD 19.5 million in an IPO, selling 3.9 million shares at USD 5 per share on the NASDAQ. The company will use the funding to advance the clinical development of its product INT230-6 for solid tumors and to expand its pipeline. Intensity Therapeutics is exploring new markets in regions beyond North America and Europe, although specific details and timelines for these expansions have not been disclosed.

## Funding rounds

- Series A, Jun 28, 2016, $10M — SEED Innovations, VCapital, SalvaRx Group PLC

## Investors

- SEED Innovations (https://capitalatlas.ai/funds/seed-innovations) — Series A
- VCapital (https://capitalatlas.ai/funds/vcapital) — Series A
- SalvaRx Group PLC — Series A